Quantification of PFS Effect for Accelerated Approval of Oncology Drugs
Author:
Chen Cong,Sun Linda Z.
Publisher
Springer New York
Reference21 articles.
1. Code of Federal Regulations- 21 CFR 314 and 601. Accelerated Approval Rule, 1992.
2. Burzykowski T, Buyse M, Yothers G, Sakamoto J and Sargent D. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Analysis 2008; 14: 54-64.
3. Sargent D, Wieand S, Haller DG et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 20, 898 patents on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
4. Tang PA, Bentzen SM, Chen EX, and Siu LL. Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy. Journal of Clinical Oncology 2007; 25: 4562-4568.
5. Miksad RA, Zietemann V, Gothe R, et al. Progression-free-survival as a surrogate endpoint in advanced breast cancer. International Journal of Technology Assessment in Health Care 2008; 24: 371-383.